The Future of Health Economic Modeling: Have We Gone Too Far or Not Far Enough?  by Fendrick, A. Mark
Volume 9 • Number 3 • 2006
V A L U E  I N  H E A L T H
© 2006, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 1098-3015/06/179 179–180 179
10.1111/j.1524-4733.2006.00115.x
Blackwell Publishing IncMalden, USAVHEValue in Health1098-30152006 Blackwell Publishing200693179180CommentaryCommentaryFendrick
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A. Mark Fendrick, MD
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This is a summary of the presentation given by A.
Mark Fendrick at the ISPOR 10th Annual Interna-
tional Meeting Second Plenary Session, May 17, 2005,
Washington, DC, USA. Dr Fendrick is Professor at the
Department of Internal Medicine and Health Manage-
ment & Policy, University of Michigan Medical
Center, Ann Arbor, MI, USA. This presentation imme-
diately followed the presentation, Bringing Health
Economic Modeling to the 21st Century, by David
Eddy.
As clinicians, we have to remind ourselves of the real
motivation for health-care modeling. The development
of models—like all clinical research methods—is a tool
to help patients, to help the health-care systems act
more efﬁciently, and ultimately, to achieve the goals of
providing high quality and value in health-care services.
Have models had an impact? There is some evi-
dence, although scant, that modeling does impact
guideline development and reimbursement decisions.
One large challenge, however, is that ultimately most
“do we, don’t we?” decisions are still being made by
clinicians at the bedside. There is virtually no evidence
suggesting that models alone affect what clinicians do.
Thus, we should not be overly optimistic that “better”
models will ultimately change how we practice medi-
cine. As we look into the future, the question to be
asked is: Will models, no matter how complex or how
simple, ever be accepted as a real time decision-making
tool? Can we ever rely on the computer alone, as in
2001: A Space Odyssey, and put the trialists out of
business except for the sole purpose of being able to
validate an existing model?
In my view, the motivation for “incremental” mod-
eling acceptance is quite straightforward: address the
questions for which rigorous evidence is not currently
available. On the success side of the equation, model-
lers have used a synthesis of data from various sources
to extend the duration of trials, to examine popula-
tions not included in trials, or to address those ques-
tions for which trial data do not exist. Clearly, one
advantage is the relative cost of simulations when com-
pared with the real cost of collecting empiric data. As
we acknowledge how expensive it is to do trials, it is
important to remember that it may be quite compli-
cated to obtain all this information for models, partic-
ularly for those clinical conditions that are less widely
studied. Modeling in this context has been quite use-
ful in  deﬁning  or  reﬁning  research  questions.  Many
in the community are quick to recognize these exer-
cises as hypothesis-generating when compared with
hypothesis-testing.
After examining David Eddy’s review of Markov
models and the newer calculus-driven models, a fun-
damental question about models that arises is “How
good is good enough?” The answer depends on the
speciﬁc clinical or policy question. In many situations,
the answer can be found in a rather short period of
time (i.e., back of the envelope), or at least approached
fairly efﬁciently, with data already available. To deter-
mine a model’s relevance, we need to ask “What do we
know already?” It is fascinating when people outside
the clinical ﬁeld query “Why are you spending so
much time simulating those diseases where the best tri-
als have already been done?” I think there is some cre-
dence to the argument that we have been inefﬁcient in
our efforts. Why not devote our attention to those
areas of surgical interventions or other rare clinical
scenarios where there really are little or no data? Some
of my colleagues in clinical medicine are almost prac-
ticing in a data-free environment. We need to deter-
mine what resources are available and invest in those
areas where the data needs are most pressing. While
more efﬁcient allocation of modeling resources may
help, we are still unsure whether key stakeholders will
be inﬂuenced by the results.
Given the lack of enthusiasm of current models, Dr
Eddy suggests that the next generation of models must
become more “realistic” and be validated to become
widely accepted. So are reality-based models really the
answer? I think the answer is “It depends.” It is my
impression that certain questions do not require overly
complex models. And even in situations where they
would be helpful, there are concerns that data require-
ments may not be met. As is the case for cost-effective-
ness analysis, it would be interesting to examine
whether it is worth the incremental cost to go beyond
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a well-accepted, somewhat validated Markov model
and create a reality-based model that David Eddy men-
tions. While there may be disagreement regarding the
relative value of even more complex models, there
should be near universal acceptance that internal and
external validation of existing models will raise the bar
for all types of models. Validation will most certainly
raise acceptance, hopefully in the payer community,
where there is usually substantial resistance––and
sometimes frank skepticism––about this methodology
in general. My own experience in US managed care
indicates that concerns regarding accepting models, at
least on the ﬁrst glance, are not about the methodology
or the complexity of the programming (the “engine”),
but are aimed at the model’s assumptions or speciﬁc
inputs. As a result, I personally remain unconvinced
that more sophisticated models from the simulation
perspective will get us over a very high hurdle to
acceptance.
A number of issues persist when considering the
future health of economic modeling. First, and the
most important, is the need for model transparency.
The fairly prevalent “black box” model should
become a thing of the past. A corollary concern is the
growth of “pay for play” proprietary models that limit
access to a user’s willingness and ability to pay. Will
proprietary incentives lead to the development of mul-
tiple, and potentially inconsistent, models? Second is
quantifying data acquisition costs for complex models.
In the case of a well-studied condition such as diabetes,
for example, it is relatively easy to draw out the infor-
mation needed for a complex model. In other condi-
tions, however, the data simply are not there and
acquisition may be prohibitively expensive. The third
issue is dealing with conﬂicting evidence. When the
data are unequivocal, when we simply know or do not
know, the approach is rather straightforward. When
the data conﬂict, the appropriate steps are not as clear-
cut. A timely example would be cyclooxygenase–
nonsteroidal antiinﬂammatory drug (COX-2–NSAID)
conundrum regarding cardiac adverse events. There is
one placebo controlled randomized trial concluding
that the remaining COX-2 selective NSAID on the
market—celecoxib––causes an increase in adverse car-
diovascular events. A second randomized controlled
trial, with a similar design and a similar drug, indicates
that there is no effect. It is not certain how clinicians or
decision-makers would ultimately be able to use even
higher level of complex models to help answer ques-
tions, if and when trial data are conﬂicting. Unfortu-
nately, there are many clinical examples where the
available data do not shed a clear-cut answer. The last
issue worth mentioning is how best to handle new data
and the development of innovative interventions (“the
moving target”). When the new diagnostic imaging
technique, or the new drug, or the new genomic-based
intervention, appears on the horizon with very little
data available regarding its impact in the short term or
the long term, how will those innovations impact these
models? Given these concerns, it is worth repeating the
great value of models as hypothesis-generating tools,
and highlighting the limits of using many models to
yield deﬁnitive results.
In my view, if health economics modeling is to play
an increased role in the future, the ﬁeld must move for-
ward with ﬁve principles in mind. 1) Models must be
tailored to the speciﬁc question at hand and to a spe-
ciﬁc audience. We must not succumb to the request
that models become a panacea for all stakeholders
when important questions remain unresolved. 2) Val-
idation should become the norm. 3) The ability of
models to test hypotheses should not be overstated––
emphasize hypothesis generation. 4) Transparency and
proprietary concerns must be addressed. 5) The use-
fulness of models vis-à-vis their impact on decision-
making should be routinely assessed. This last princi-
ple should not be forgotten. If there is no measurable
positive impact on patients and the health-care system
at large from modeling, then all of our efforts may go
for naught.
